2004-02-18
Prolonging the exposure to anti-cancer agents
Publication
Publication
Verlenging van de expositieduur van antikankermiddelen
This thesis includes phase I clinical and pharmacological studies on second and third generation topoisomerase I inhibitors, either administered orally, or intravenously as a macromolecular drug-delivery system, and on the antimicrotubulin agent, paclitaxel encapsulated in liposomes, to investigate the suitability of prolonged exposure of these anti-cancer agents and formulations. These studies were performed since in preclinical models, the cytotoxicity of both topoisomerase I inhibitors and paclitaxel increases with duration of exposure
| Additional Metadata | |
|---|---|
| , , , | |
| Erasmus University Rotterdam | |
| J. Verweij (Jaap) , G. Stoter (Gerrit) | |
| hdl.handle.net/1765/51512 | |
| Organisation | Erasmus MC: University Medical Center Rotterdam |
|
Soepenberg, O. (2004, February 18). Prolonging the exposure to anti-cancer agents. Retrieved from http://hdl.handle.net/1765/51512 |
|
| Additional Files | |
|---|---|
| 2040_Soepenberg.jpg Cover Image , 27kb | |
| stellingen-Soepenberg.pdf , 61kb | |
| CV-Soepenberg.pdf , 494kb | |
